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Editorial 
The pathophysiological role of mucus production in 
inflammatory airway diseases 
Decrease in the forced expiratory volume within the 
first second of exhalation (FEV,) is the hallmark to 
describe the severity of various inflammatory air- 
ways diseases such as asthma, chronic bronchitis 
and cystic fibrosis (CF). To what extent airway 
mucus production affects this measurement is not 
clearly understood. We summarize the evidence sup- 
porting the role of mucus in inflammatory airway 
diseases. 
Obstruction of the lower airways may be caused by 
a variety of structural changes of the airways includ- 
ing intraluminal accumulation of mucus, hyperplasia 
and hypertrophia of the submucosal glands, inflam- 
matory reaction of the submucosal tissue leading to 
oedema and contraction of the bronchial smooth 
muscles as well as structural damage of the lung 
parenchyma leading to loss of elastic recoil. The 
influence of each of these structural changes on 
obstruction varies with the aetiology of pulmonary 
disease. 
FEV, is the best available prognostic marker in 
chronic obstructive lung disease (COLD). Several 
large epidemiological studies have assessed the pos- 
sible contribution of chronic mucus hypersecretion 
(CMH; i.e. reporting phlegm for at least 3 months 
yr - ’ in 2 consecutive yrs) to morbidity and mortality 
from COLD and the results are conflicting. Whereas 
the most widely cited study by Peto et al. (1) failed to 
detect additional prognostic information of CMH 
after adjustment for FEV, height - 3, other studies in 
more unselected populations have found patients 
with CMH to have a 20-50X increased risk of dying 
compared to patients with a similar degree of FEV, 
impairment (2). Since Fletcher et al. (3) rejected 
‘the British hypothesis’, little epidemiologic research 
has been aimed at CMH and FEV, decline. It is 
noteworthy, however, that in two of the largest 
population-based studies, presence of CMH is 
associated with excess FEV, decline (4,5). 
When assessing epidemiological studies on CMH 
it should be remembered that phlegm material is 
derived from submucosal glands in the central air- 
ways. Reed described in 1960 how submucosal gland 
cells outscore the other cellular manufacturer of 
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mucus ~ namely the goblet cell - by a ratio of 4O:l 
(6). The submucosal glands are primarily located in 
the central airways, whereas the goblet cells are more 
evenly distributed throughout the airway tree. Unfor- 
tunately, we have no specific marker of goblet cell 
activation. The importance of this point was under- 
lined by the classical study in 1968 by Hogg et al. (7), 
who demonstrated that the primary site of obstruc- 
tion in patients with COLD, but without emphy- 
sema, was the peripheral airways where hyperplasia 
of the goblet cells and mucus plugging were noted. 
Several subsequent studies have confirmed this find- 
ing. The presence of an increased number of goblet 
cells may perhaps separate patients with CMH and 
obstruction from patients with CMH but without 
obstruction (8). Thus, increased mucus production 
from goblet cells in the more peripheral airways may 
contribute to obstruction in COLD patients, in spite 
of the disputed association between phlegm and 
FEV, decline. 
Accumulation of mucus in the airway tree may 
be caused by an increased volume of mucus 
produced, and perhaps also by decreased clearance 
due to defects in the ciliary clearance apparatus. 
Mucus hypersecretion may be chronic as discussed 
above, but increased volumes are produced in 
exacerbations of COLD, during attacks of 
asthma and in CF patients with chronic bacterial 
colonization. 
The neuronal innervation of the airway tree is 
derived from all the three parts of the autonomic 
nervous system. In vitro studies have shown that 
stimulation of muscarinic receptors will result in the 
most pronounced production of mucus, whereas 
p-adrenergic stimulation has not been shown to affect 
mucus production in human lower airways (9). Inhi- 
bition of muscarinic receptors will result in inhibition 
of mucus production but the therapeutic applicability 
is not clear. Other neurotransmitters (especially 
neuropeptides such as substance P) may modulate 
mucus production, but their definitive role in airway 
diseases has not been defined, primarily because no 
effective and easily available antagonist for use in 
humans has been developed yet. 
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The hallmark of inflammatory airway diseases 
is the accumulation of inflammatory cells. The 
predominant cell type may, to some extent, depend 
on the type of airway disease. In asthmatic airways, 
eosinophils are characteristic whereas neutrophils 
may accumulate in the airways after exposure to 
tobacco smoke and bacterial infections. The influence 
of inflammatory cells on the production of mucus has 
been intensively studied. Monocytes/macrophages, 
neutrophils and eosinophils contain proteins and 
lipid inflammatory mediators capable of stimulating 
mucus production in human airway cultures. The 
accumulation of inflammatory cells may be prevented 
by anti-inflammatory drugs such as glucocorticoids, 
and also, possibly, theophylline (10). In addition, 
glucocorticoids may directly inhibit the production of 
mucus from glands. 
The viscosity of mucus is primarily dependent on 
the glycoproteins produced in the submucosal glands 
and the goblet cells. DNA derived from inflamma- 
tory cells enhances the viscosity markedly. Genetic 
defects leading to increased mucus viscosity of CF 
patients but also DNA from inflammatory cells may 
contribute significantly to obstruction in patients 
with chronic Pseudomonas airway infections. The 
viscosity of DNA-containing mucus can be decreased 
after treatment with DNase (i.e. the enzyme which 
cleaves DNA). Recently published controlled studies 
using recombinant DNase in chronic pseudomonas 
infected CF patients have shown decreased obstruc- 
tion and decreased risk of exacerbations (1 l), under- 
lining that mucus accumulation due to increased 
viscosity plays a central role in the impaired lung 
function of these patients. 
In conclusion, several epidemiological, clinical and 
laboratory results indicate that airway mucus plays 
an important role in the pathophysiology of airway 
inflammatory diseases, including COLD. However, 
more research should be devoted to improving the 
detection of mucus derived from various areas of the 
airway tree. Bronchial and bronchoalveolar lavages 
should be carefully studied in this respect. Subse- 
quently, we may be able to better assess the influence 
and importance of therapeutic agents in controlling 
mucus production. 
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